ZimVie Inc
NASDAQ:ZIMV
ZimVie Inc
Zimvie, Inc. operates as a holding company, which engages in the manufacture, design, and distribution of medical devices and surgical instruments. The company is headquartered in Westminster, Colorado and currently employs 2,700 full-time employees. The company went IPO on 2022-02-14. The firm develops, manufactures, and markets a portfolio of products and solutions designed to treat a range of spine pathologies and support dental tooth replacement and restoration procedures. The Company’s operations are managed on a products basis and include two operating segments: the spine products segment, and the dental products segment. Its spine products segment focused on designing, manufacturing, and distributing medical devices and surgical instruments to deliver solutions for individuals with back or neck pain caused by degenerative conditions, deformities, tumors, or traumatic injury of the spine. Its product portfolio includes Mobi-C Cervical Disc and the Tether device. Its dental products segment is focused on designing, manufacturing and/or distributing of dental implant solutions. Its products include T3 Implant, Tapered Screw-Vent Implant System, Trabecular Metal Dental Implant, and BellaTek Encode Impression System.
Zimvie, Inc. operates as a holding company, which engages in the manufacture, design, and distribution of medical devices and surgical instruments. The company is headquartered in Westminster, Colorado and currently employs 2,700 full-time employees. The company went IPO on 2022-02-14. The firm develops, manufactures, and markets a portfolio of products and solutions designed to treat a range of spine pathologies and support dental tooth replacement and restoration procedures. The Company’s operations are managed on a products basis and include two operating segments: the spine products segment, and the dental products segment. Its spine products segment focused on designing, manufacturing, and distributing medical devices and surgical instruments to deliver solutions for individuals with back or neck pain caused by degenerative conditions, deformities, tumors, or traumatic injury of the spine. Its product portfolio includes Mobi-C Cervical Disc and the Tether device. Its dental products segment is focused on designing, manufacturing and/or distributing of dental implant solutions. Its products include T3 Implant, Tapered Screw-Vent Implant System, Trabecular Metal Dental Implant, and BellaTek Encode Impression System.
Revenue: ZimVie reported Q1 2025 revenue of $112 million, down 5.2% year-over-year, reflecting a soft market but in line with guidance.
Profitability: Adjusted EBITDA reached $17.6 million and margin improved to 15.7%, a 520 basis point increase, exceeding the company’s target.
Cost Control: Adjusted total cost of products sold fell by over 350 basis points, supported by manufacturing and supply chain efficiencies.
Guidance Reiterated: Full-year 2025 guidance for revenue ($445–460 million), adjusted EBITDA ($65–70 million), and EPS ($0.80–0.95) were all maintained.
Product Launch & Mix: The new immediate molar implant exceeded internal growth expectations and is expected to be a growth driver for the year.
Tariffs: Management expects to absorb an annual $3 million tariff impact within guidance using supply chain flexibility.
Digital & Biomaterials: Digital dentistry solutions (excluding scanner sales) grew at a high single-digit rate; biomaterials grew just over 1%.
Strategic Acquisition: ZimVie acquired its Costa Rica distributor, expected to immediately benefit margins and expand local presence.
